Mandate

Vinge advised IBT on its Nasdaq Stockholm main market listing

September 10, 2018 Capital Markets and Public M&A

The shares of Infant Bacterial Therapeutics AB (publ) have been admitted to trading on the main market of Nasdaq Stockholm (Mid Cap).

 Vinge advised IBT.

The Vinge team included Erik Sjöman, Christian Lindhé and Astrid Karlsson..
 

Related

Vinge advises Symrise on its public offer for Probi

Symrise AG has announced a public cash offer to the shareholders of Probi AB (publ) (“Probi”). The offer values Probi at approximately SEK 3,988 million. The shares in Probi are traded on Nasdaq Stockholm, Mid Cap.
November 20, 2024

Vinge advises Oxx in conjunction with an investment in Kodiak Hub

Kodiak Hub, a Swedish software as a service (SaaS) company, which offers its customers an AI-based software platform, has performed a capital procurement of EUR 6 million. The venture capital fund Oxx, which invests in SaaS companies, is the largest investor.
November 20, 2024

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited

Semmco Group is a UK market-leading manufacturer and supplier of maintenance platforms and stairs for aircraft and trains.
November 19, 2024